Forendo Pharma

OverviewSuggest Edit

Forendo Pharma is a drug development company focusing on novel treatments in women's health. Its pipeline includes HSD17B1 inhibitor, FOR-6219 for the treatment of endometriosis; dual HSD inhibitors for the treatment of broader gynecological conditions; and Fispemifene, a novel SERM for the treatment of male urological conditions.

TypePrivate
Founded2013
HQÅbo, FI
Websiteforendo.com

Latest Updates

Employees (est.) (Jun 2021)25
Cybersecurity ratingAMore

Key People/Management at Forendo Pharma

Risto Lammintausta

Risto Lammintausta

CEO & Director

Forendo Pharma Office Locations

Forendo Pharma has an office in Åbo
Åbo, FI (HQ)
Österlånggatan 4b
Show all (1)

Forendo Pharma Financials and Metrics

Summary Metrics

Founding Date

2013

Forendo Pharma total Funding

$30.7 m

Forendo Pharma latest funding size

$5.61 m

Time since last funding

2 years ago

Forendo Pharma investors

Forendo Pharma's latest funding round in July 2019 was reported to be $5.6 m. In total, Forendo Pharma has raised $30.7 m
Show all financial metrics

Forendo Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Forendo Pharma Online and Social Media Presence

Embed Graph

Forendo Pharma News and Updates

Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data

STOCKHOLM, SWEDEN – March 3, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company, Forendo Pharma, has successfully completed a Phase 1 program for FOR-6219 – a candidate drug aimed for the treatment of endometriosis. Based on the positive results gener…

Karolinska Development’s portfolio company Forendo Pharma enters license and collaboration agreement with leading pharma company

STOCKHOLM, SWEDEN – December 11, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has entered a license and collaboration agreement with the global pharmaceutical company Novartis to develop new drugs for the treatment of chronic liver d…

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endome…

Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219

STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endome…

Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-6219

TURKU, Finland, Aug. 20, 2019 /PRNewswire/ -- Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of...

Forendo Pharma Blogs

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully conclude…

Forendo Pharma Appoints Dr Cristina Csimma as Chair of the Board of Directors

Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women’s health, today announced that Dr Cristina Csimma has been appointed as Chair of the Board of Directors. Cristina brings with her deep expertise in the biopharmaceutical, venture capital, and academic sec…

Biotech in Europe Forum

Forendo is attending the Biotech in Europe Forum 21st -24th of September. The 20th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together…

Forendo Pharma signs important License and Collaboration Deal with Leading Pharma Company

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces signing of a License and Collaboration Agreement with Novartis. The joint research collaboration is aimed at the identification of novel drugs for the treatment of chronic liver …

Endometriosis program Phase 1b Proof of Mechanism Study initiated

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism. The novel oral compound, FOR-6219, is a HSD17B…

Forendo Pharma Frequently Asked Questions

  • When was Forendo Pharma founded?

    Forendo Pharma was founded in 2013.

  • Who are Forendo Pharma key executives?

    Forendo Pharma's key executives are Risto Lammintausta.

  • How many employees does Forendo Pharma have?

    Forendo Pharma has 25 employees.

  • Who are Forendo Pharma competitors?

    Competitors of Forendo Pharma include Fervent Pharmaceuticals, HRA Pharma and Ascend Therapeutics.

  • Where is Forendo Pharma headquarters?

    Forendo Pharma headquarters is located at Österlånggatan 4b, Åbo.

  • Where are Forendo Pharma offices?

    Forendo Pharma has an office in Åbo.

  • How many offices does Forendo Pharma have?

    Forendo Pharma has 1 office.